An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With Terminal Cancer-Related Pain Refractory to Strong Opioid Analgesics
- 1 August 2013
- journal article
- research article
- Published by Elsevier BV in Journal of Pain and Symptom Management
- Vol. 46 (2), 207-218
- https://doi.org/10.1016/j.jpainsymman.2012.07.014
Abstract
No abstract availableKeywords
Funding Information
- GW Pharma Ltd.
- GW Pharma Ltd.
This publication has 28 references indexed in Scilit:
- Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trialsSupportive Care in Cancer, 2010
- Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related PainJournal of Pain and Symptom Management, 2009
- Cannabinoid–opioid interactions during neuropathic pain and analgesiaCurrent Opinion in Pharmacology, 2009
- The orphan receptor GPR55 is a novel cannabinoid receptorBritish Journal of Pharmacology, 2007
- Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trialPain, 2007
- The Epidemiology of Cancer PainCancer Investigation, 2005
- The Epidemiology of Cancer PainCancer Investigation, 2005
- Modulation of the release of endogenous adenosine by cannabinoids in the myenteric plexus-longitudinal muscle preparation of the guinea-pig ileumBritish Journal of Pharmacology, 2002
- International Union of Pharmacology. XXVII. Classification of Cannabinoid ReceptorsPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2002
- Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scalePain, 2001